Analytical Data
-
Gene name
APOA4
- Application
-
Alternative Names
APOA4；ApolipoProtein A-IV
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P06727
-
Expression Region
1-396aa
-
AA Sequence
MFLKAVVLTLALVAVAGARAEVSADQVATVMWDYFSQLSNNAKEAVEHLQ KSELTQQLNALFQDKLGEVNTYAGDLQKKLVPFATELHERLAKDSEKLKE EIGKELEELRARLLPHANEVSQKIGDNLRELQQRLEPYADQLRTQVNTQA EQLRRQLTPYAQRMERVLRENADSLQASLRPHADELKAKIDQNVEELKGR LTPYADEFKVKIDQTVEELRRSLAPYAQDTQEKLNHQLEGLTFQMKKNAE ELKARISASAEELRQRLAPLAEDVRGNLRGNTEGLQKSLAELGGHLDQQV EEFRRRVEPYGENFNKALVQQMEQLRQKLGPHAGDVEGHLSFLEKDLRDK VNSFFSTFKEKESQDKTLSLPELEQQQEQQQEQQQEQVQMLAPLES
-
Molecular Weight
72 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein A-IV (APOA4) is a key protein involved in lipid metabolism and is primarily synthesized in the intestine and liver. It plays a crucial role in the transport of lipids in plasma, particularly triglycerides and cholesterol. Research into APOA4 has gained significant attention due to its potential implications in cardiovascular health and metabolic disorders such as obesity and diabetes. Studies have shown that APOA4 may influence cholesterol efflux, reduce atherosclerosis risk, and modulate the apolipoprotein composition of lipoprotein particles, thereby impacting lipid profiles and inflammatory responses. Additionally, variations in the APOA4 gene have been associated with altered lipid levels and increased susceptibility to heart disease. Given its multifaceted role in lipid metabolism and disease, the recombinant expression of APOA4 is being explored for therapeutic applications, including enhancing HDL function and reducing cardiovascular risk. Further investigations into the structure-function relationship of APOA4 and its interactions with lipids and other proteins are essential for understanding its physiological roles and developing novel therapeutic strategies targeting metabolic diseases. The creation of recombinant APOA4 proteins provides a valuable tool for these studies, facilitating the exploration of its biochemical properties and potential applications in clinical settings.
